MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
9.65
+0.32
+3.43%
After Hours: 9.47 -0.18 -1.87% 17:16 07/14 EDT
OPEN
9.28
PREV CLOSE
9.33
HIGH
9.68
LOW
9.17
VOLUME
607.58K
TURNOVER
--
52 WEEK HIGH
18.98
52 WEEK LOW
6.50
MARKET CAP
1.02B
P/E (TTM)
-2.3021
1D
5D
1M
3M
1Y
5Y
1D
Gilead Sciences and Arcus Biosciences: New Lung Cancer Treatment Combinations Under Evaluation
TipRanks · 14h ago
Weekly Report: what happened at RCUS last week (0707-0711)?
Weekly Report · 21h ago
Arcus Biosciences’ cancer drug gets orphan drug status
Seeking Alpha · 4d ago
Arcus Biosciences' Pancreatic Cancer Treatment Gets Orphan Drug Status
Dow Jones · 4d ago
Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer
NASDAQ · 4d ago
Arcus Biosciences quemliclustat granted orphan drug designation by FDA
TipRanks · 4d ago
Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet?
Simply Wall St · 4d ago
Arcus Biosciences Announces New Employment Inducement Grants
Barchart · 5d ago
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.